IRIS
PARENTI, Carmela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.019
EU - Europa 3.781
AS - Asia 3.639
SA - Sud America 580
AF - Africa 544
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 5
Totale 17.579
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.743
SG - Singapore 1.952
CN - Cina 1.147
IT - Italia 1.041
RU - Federazione Russa 904
IE - Irlanda 615
UA - Ucraina 536
BR - Brasile 510
CI - Costa d'Avorio 374
CA - Canada 237
DE - Germania 188
VN - Vietnam 131
SE - Svezia 105
SN - Senegal 103
GB - Regno Unito 92
KR - Corea 88
IN - India 70
JP - Giappone 58
FR - Francia 46
FI - Finlandia 39
PL - Polonia 33
ES - Italia 32
NL - Olanda 30
BD - Bangladesh 28
MX - Messico 28
ID - Indonesia 27
AR - Argentina 25
BE - Belgio 25
UZ - Uzbekistan 20
ZA - Sudafrica 20
HK - Hong Kong 19
AT - Austria 17
CH - Svizzera 17
TR - Turchia 16
IQ - Iraq 15
CZ - Repubblica Ceca 14
GR - Grecia 11
PK - Pakistan 11
AE - Emirati Arabi Uniti 10
AU - Australia 10
BJ - Benin 10
EC - Ecuador 10
IR - Iran 8
MA - Marocco 8
VE - Venezuela 8
CL - Cile 7
CO - Colombia 7
DZ - Algeria 7
HU - Ungheria 7
LB - Libano 7
EG - Egitto 6
IL - Israele 6
LT - Lituania 6
PE - Perù 6
TH - Thailandia 6
BG - Bulgaria 5
EU - Europa 5
SA - Arabia Saudita 5
AL - Albania 4
KE - Kenya 4
NG - Nigeria 4
NO - Norvegia 4
PY - Paraguay 4
TN - Tunisia 4
AZ - Azerbaigian 3
AO - Angola 2
BB - Barbados 2
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
NP - Nepal 2
OM - Oman 2
RS - Serbia 2
SV - El Salvador 2
UY - Uruguay 2
AM - Armenia 1
BO - Bolivia 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GP - Guadalupe 1
HR - Croazia 1
JM - Giamaica 1
JO - Giordania 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LK - Sri Lanka 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
TL - Timor Orientale 1
TT - Trinidad e Tobago 1
Totale 17.579
Salva come PNG Salva come JPEG
Città #
Dallas 1.712
Singapore 1.089
Houston 1.024
Santa Clara 1.012
Chandler 794
Dublin 611
Jacksonville 513
Chicago 468
Abidjan 374
Ashburn 367
Moscow 337
Catania 333
Boardman 289
Nanjing 190
Beijing 177
Hefei 174
Cambridge 173
Lawrence 173
Andover 171
Toronto 160
Los Angeles 121
Dakar 103
Civitanova Marche 94
Wilmington 94
Seoul 88
San Mateo 87
Bremen 83
Des Moines 71
Council Bluffs 70
Nanchang 65
Buffalo 58
Columbus 52
Shenyang 52
New York 51
São Paulo 51
The Dalles 51
Tokyo 51
Saint Petersburg 46
Jiaxing 42
Ottawa 42
Rome 42
Changsha 40
Ho Chi Minh City 40
Munich 39
Tianjin 38
Hebei 34
Grafing 32
Naples 31
Hanoi 28
Brussels 24
Warsaw 22
Brooklyn 21
Denver 20
Jakarta 19
Rio de Janeiro 18
Seattle 18
Turku 18
Dong Ket 17
Falls Church 17
Pune 17
Atlanta 16
Hong Kong 16
Messina 16
Montreal 16
Jinan 15
Johannesburg 15
Ningbo 15
Norwalk 15
Belo Horizonte 14
San Giovanni la Punta 14
Amsterdam 13
Augusta 13
Helsinki 13
Washington 13
Boston 12
Mascalucia 11
Orem 11
Phoenix 11
Zhengzhou 11
Campinas 10
Cotonou 10
London 10
Milan 10
Palermo 10
Paternò 10
Poplar 10
San Francisco 10
Stockholm 10
Chennai 9
Kunming 9
Leawood 9
Madrid 9
Salerno 9
Salvador 9
Ann Arbor 8
Fremont 8
Fuzhou 8
Haiphong 8
Liberty Lake 8
Mumbai 8
Totale 12.500
Salva come PNG Salva come JPEG
Nome #
Wilms' tumor gene 1 silencing inhibits proliferation of human osteosarcoma MG-63 cell line by cell cycle arrest and apoptosis activation. 439
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation 397
NOP RECEPTOR ANTAGONISM IN THE VENTROLATERAL PERIAQUEDUCTAL GRAY ATTENUATES THE DEVELOPMENT OF OPIOID TOLERANCE. 321
((2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist 288
The simultaneous activation of μ- and δ-opioid receptors by (−)-2S-LP2 rescues allodynia with the contribution of TGF-β1 signaling in a rat chronic constriction injury model 206
Involvement of sigma 2 receptor on motor disorder 191
Neuroprotective effects of Rosmarinus officinalis L. extract in oxygen glucose deprivation (OGD)-injured human neural-like cells 181
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 174
Do vitamins halt the COVID-19-evoked pro-inflammatory cytokines involved in the development of neuropathic pain? 172
Inhibition of Cx43 mediates protective effects on hypoxic/reoxygenated human neuroblastoma cells 159
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review 158
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 155
Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis 151
A new sigma ligand, (+/-)-PPCC, antagonizes kappa opioid receptor-mediated antinociceptive effect 147
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 145
Connexins in the central nervous system: physiological traits and neuroprotective targets 139
R- ed S-LP2: sintesi, molecular docking e valutazione farmacologica 137
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 136
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 136
CHF5074 protects SH-SY5Y human neuronal-like cells from amyloidbeta 25-35 and tumor necrosis factor related apoptosis inducing ligand toxicity in vitro 133
Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review 130
ANTIALLODINIC AND ANTIHYPERALGESIC EFFECTS OF LP1, AN OPIOID MULTITARGET LIGAND, IN INFLAMMATORY AND NEUROPATHIC PAIN STATES 128
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. 127
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 127
Development of novel LP1-based analogues with enhanced delta opioid receptor profile 123
Chronic treatment with fluoxetine induces sex-dependent analgesic effects and modulates HDAC2 and mGlu2 expression in female mice 123
The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling 123
Sigma-1 Receptor Inhibition Reduces Mechanical Allodynia and Modulate Neuroinflammation in Chronic Neuropathic Pain 120
Intercellular communication and ion channels in neuropathic pain chronicization 119
Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands 116
Effect of supraspinal Nocistatin on nociceptin/OrphaninFQ antagonism of selective opioid analgesia 115
Dual MOR/DOR agonist benzomorphan-based compounds for pain relief 115
Central and peripheral control by endogenous opioid peptides of gastric protection in stressed-rats 115
MOR/DOR targeting: an useful strategy in pain management 114
LP2 e 2S-LP2: agonisti biased dual target MOR/DOR nel trattamento del dolore cronico 113
Apoptotic effects of (±) MRJF4 in prostate cancer cells 112
Sigma-2 receptor ligands QSAR model dataset 112
Activity of profens as racemic (R and S) enantiomers in human condrocytes and cartilage 111
(+)-Mr200 derivatives: modifications on the amino moiety. In vitro and in vivo pharmacological evaluation 110
A New LP1 analogue is used to better understand MOR ligand Binding Domain and its mechanisms of activation 110
Lipid Nanoparticle Inclusion Prevents Capsaicin-Induced TRPV1 Defunctionalization 110
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 109
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 109
From plant to bench: natural products as source for analgesic drug development. 109
Activity of profens as racemic (R and S) enantiomers in human condrocytes and cartilage 108
An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain 108
Blockade of the nociceptin/orphanin FQ/NOP receptor system in the rat ventrolateral periaqueductal gray potentiates DAMGO analgesia 108
In Vitro Antioxidant Activity and In Vivo Topical Efficacy of Lipid Nanoparticles Co-Loading Idebenone and Tocopheryl Acetate 108
Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain 107
Studio aerobiologico e incidenza di pollinosi nella popolazione acese 106
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation. 105
Ischemic tolerance modulates TRAIL expression and its receptors and generates a neuroprotected phenotype 105
Antiallodinic and antihyperalgesic effects of LP1, an opioid multitarget ligand, in inflammatory and neurophatic pain states 105
Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain 105
Involvement of the Heme-Oxygenase Pathway in the Antiallodynic and Antihyperalgesic Activity of Harpagophytum procumbens in Rats. 104
Neuroprotective effect of the new sigma receptor ligands cis-(+) and cis-(–)-PPCC 104
Tumor necrosis factor-related apoptosis-inducing ligand reduces the expression of the neuroprotective Na+ /Ca2+ exchanger isoform NCX3 in human neuroblastoma SH-SY5Y cells 104
Effect of CCK-8 on analgesia induced by cold-restraint stress in the rat 103
ANTIALLODYNIC AND ANTIHYPERALGESIC EFFECTS OF INTRAPLANTAR NOCISTATIN AND (±)-J 113397 IN INFLAMMATORY PAIN 103
Central and peripheral involvement of endogenous opioid peptides in gastric protection in stressed rats 102
Novel Sigma-1 receptor antagonists: From opioids to small molecules: What is new? 101
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity 99
New Insights into the Opioid Analgesic Profile of cis-(-)-N-Normetazocine-derived Ligands 98
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain 98
The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment 98
Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management 98
Antiallodynic and antihyperalgesic effects of intraplantar nocistatin and (+/-)-J113397 in inflammatory pain 97
Dual-target ligands and pain: our experience 96
Multitarget opioid ligands in pain relief: New players in an old game 96
Wilms’ Tumor Gene 1 (WT1) silencing inhibits proliferation of malignant peripheral nerve sheath tumor sNF96.2 cell line 96
Repeated activation of delta opiod receptors counteracts nerve injury-induced TNF-α up-regulation in the sciatic nerve of rats with neuropathic pain: A possible correlation with delta opiod receptors-mediated antiallodinic effect. 96
The benzomorphan-based compound LP1 is a central acting MOR agonist/DOR antagonist suitable for chronic pain treatment 93
Evaluation of N-substituent structural variations in opioid receptor profile of LP1. 93
Preclinical evidence of enhanced analgesic activity of duloxetine complexed with succinyl-β-cyclodextrin: A comparative study with cyclodextrin complexes 93
Effects of dinorphin 1-13 on hyperalgesia induced by interleukin-1bera in the rat 91
Effect of centrally administered -B-endorphin on the development of stress-induced gastric ulcers in rats 91
Prevention of stress-induced gastric ulcers by mu- and delta-opioid agonists in the rat. 90
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 90
From Plant to Chemistry: Sources of Antinociceptive Non-Opioid Active Principles for Medicinal Chemistry and Drug Design 89
In-vitro evaluation of a new benzomorphan-based ligand 89
The Benzomorphan-Based Compound LP1 as Suitable Candidate for Pain Management 89
Different in vitro activity of flurbiprofen and its enantimers on human articular cartilage 89
Effects of a Selective Sigma 1 Antagonist Compound on Inflammatory Pain 89
Progress in the development of more effective and safer analgesics for pain management 89
Wilms' tumor 1 (WT1) protein expression in human developing tissues 88
Scouting new sigma receptor ligands: Synthesis, pharmacological evaluation and molecular modeling of 1,3-dioxolane-based structures and derivatives 88
Rosemary Essential Oil-Loaded Lipid Nanoparticles: In Vivo Topical Activity from Gel Vehicles 87
Novel sigma 1-antagonists with cis-(+)-normetazocine scaffold: synthesis, molecular modeling, and antinociceptive effect 86
Rescue of noradrenergic system as a novel pharmacological strategy in the treatment of chronic pain: Focus on microglia activation 86
Hybrid MOR agonist/HDACi molecules as potential antinociceptive multi-target drugs: design, synthesis, and biological evaluation 85
Pain management: new long-acting opioid ligands 85
Harpagophytum procumbens extract potentiates morphine antinociception in neuropathic rats. 85
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 84
Evaluation of N-substitution in 6,7-benzomorphan compounds 83
Idebenone: Novel strategies to improve its systemic and local efficacy 83
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures 83
HDAC and HAT inhibitors differently affect analgesia mediated by group II metabotropic glutamate receptors 82
Involvement of the Nociceptin/Orphanin FQ-NOP receptor system in the ventrolateral periaqueductal gray following mechanical allodynia in chronic pain 80
THE BENZOMORPHAN-BASED COMPOUND LP1 AS A MULTITARGET OPIOID LIGAND FOR CHRONIC PAIN TREATMENT 80
Effect of arachidonic acid on pituitary immunoreactive B-endorphin levels in the rat 80
Totale 12.043
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.593
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.593
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021518 0 0 0 0 0 35 106 8 110 16 170 73
2021/20221.382 163 178 15 38 210 16 186 56 123 23 56 318
2022/20232.419 196 127 46 291 214 378 8 439 512 45 101 62
2023/20241.265 82 218 78 62 68 286 48 76 2 33 218 94
2024/20254.084 67 747 214 236 877 480 196 188 243 321 243 272
2025/20265.281 527 340 1.908 455 1.315 736 0 0 0 0 0 0
Totale 18.021